Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib maintenance therapy for platinum-sensitive recurrent ovarian-related cancers
ChiCTR2600134768Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of senaparib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Union Hospital. Primary endpoint: 1-year progression-free survival rate. Started Oct 2025; status: recruiting.
02
Drugs
senaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR2600134768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134768.